Marinus Pharmaceuticals Inc (NASDAQ:MRNS) CEO Christopher Michael Cashman sold 9,566 shares of the company’s stock in a transaction on Thursday, January 18th. The shares were sold at an average price of $6.28, for a total value of $60,074.48. Following the completion of the sale, the chief executive officer now owns 247,903 shares in the company, valued at $1,556,830.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Marinus Pharmaceuticals Inc (NASDAQ MRNS) traded up $0.71 during midday trading on Monday, reaching $7.54. The company had a trading volume of 2,363,181 shares, compared to its average volume of 1,850,000. Marinus Pharmaceuticals Inc has a 1 year low of $1.06 and a 1 year high of $9.87. The stock has a market capitalization of $305.25, a P/E ratio of -8.11 and a beta of 2.44.

Marinus Pharmaceuticals (NASDAQ:MRNS) last released its earnings results on Tuesday, October 31st. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.17) by $0.02.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp purchased a new position in Marinus Pharmaceuticals during the third quarter worth about $128,000. Citadel Advisors LLC lifted its position in Marinus Pharmaceuticals by 327.8% during the third quarter. Citadel Advisors LLC now owns 51,383 shares of the biopharmaceutical company’s stock worth $301,000 after buying an additional 39,371 shares during the period. Susquehanna International Group LLP purchased a new position in Marinus Pharmaceuticals during the third quarter worth about $503,000. EAM Investors LLC purchased a new position in Marinus Pharmaceuticals during the third quarter worth about $554,000. Finally, Iguana Healthcare Management LLC purchased a new position in Marinus Pharmaceuticals during the third quarter worth about $1,027,000. Hedge funds and other institutional investors own 49.78% of the company’s stock.

Several analysts have recently issued reports on MRNS shares. BidaskClub upgraded Marinus Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, December 30th. Laidlaw started coverage on Marinus Pharmaceuticals in a research report on Thursday, December 14th. They issued a “buy” rating and a $18.00 price objective on the stock. Finally, ValuEngine downgraded Marinus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, December 1st.

WARNING: This report was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another website, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this report can be accessed at https://www.thecerbatgem.com/2018/01/22/insider-selling-marinus-pharmaceuticals-inc-mrns-ceo-sells-9566-shares-of-stock.html.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.

Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.